Keryx Biopharmaceuticals to Present at Friedman Billings Ramsey 9th Annual Growth Conference

NEW YORK, May 27, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. , announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the Company, including recent clinical results and upcoming milestones at the Friedman Billings Ramsey 9th Annual Growth Conference in New York City. Mr. Weiss' presentation will take place on Wednesday, June 1, 2005 at 9:00 a.m. Eastern Time in Room 5.04 of the Millennium Hotel Broadway. A live audio webcast of Mr. Weiss' presentation will be available at http://www.wsw.com/webcast/fbr10/kerx/. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound for the treatment of diabetic nephropathy, which is in a Phase 2 clinical program and for which a pivotal Phase 3 and Phase 4 program is pending commencement under an SPA with the FDA. Additionally, Keryx is developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt and other important signal transduction pathways, which is in Phase 2 clinical development. Keryx also has an active in-licensing and acquisition program designed to identify and acquire clinical-stage drug candidates. Keryx Biopharmaceuticals is headquartered in New York City.

Contact:  Keryx Biopharmaceuticals, Inc.
          Ron Bentsur, Vice President, Finance & Investor Relations
          (212) 531-5965
          ron@keryx.com